SRZN
Surrozen, Inc.
NASDAQ · USHealthcareBiotechnology
$22.16+0.91%
Price as of Jul 20, 2026
SRZN growth
Surrozen, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -35.6%
- EBITDA
- —
- EBIT
- -65.6%
- EPS
- -66.3%
- Free cash flow
- -85.0%
- Operating cash flow
- -84.2%
Forward estimates
- Revenue
- -65.0%
- EBITDA
- +100.2%
- EPS
- +90.2%
Three-year CAGR
- Revenue
- -34.7%
- EBITDA
- —
- EBIT
- -64.8%
- Net income
- —
- EPS
- -49.4%
- Free cash flow
- -72.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.